<style draggable="dTgtdP"><noframes date-time="86KJLh"><code dropzone="wUVOf0"></code>
2016
DOI: 10.1200/jco.2015.64.0391
|Get access via publisher |Cite
|
Sign up to set email alerts

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

Abstract: Purpose We evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in patients with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Patients received pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks. Atypical responses were iden… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

18
507
3
15

Year Published

2016
2016
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations

Cited by 700 publications

(543 citation statements)
references

References 25 publications

18
507
3
15
Order By: Relevance